This is the first study from my lab - providing the first PoC for both linear and cyclic untargeted binder design! EvoBind is available here: github.com/patrickbryan...
22.07.2025 11:23 β π 1 π 0 π¬ 0 π 0@patrickbryant1.bsky.social
Assistant Professor at Stockholm University. Dedicated Scientist.
This is the first study from my lab - providing the first PoC for both linear and cyclic untargeted binder design! EvoBind is available here: github.com/patrickbryan...
22.07.2025 11:23 β π 1 π 0 π¬ 0 π 0Our study where we develop EvoBind2: Design of linear and cyclic peptide binders from protein sequence information is now published! www.nature.com/articles/s42...
22.07.2025 11:23 β π 3 π 2 π¬ 1 π 0Cool! Congrats @proteinator.bsky.social π
17.07.2025 05:49 β π 2 π 0 π¬ 0 π 0We have much more coming in this space where we can identify target interfaces and inhibit the interactions - all using protein structure prediction!
06.07.2025 08:02 β π 0 π 0 π¬ 0 π 0Now published: our study on human-pathogen protein-protein interactions! We identify 30 interactions with an expected TM-score β₯0.9, tripling the structural coverage in these networks. One novel interaction was validated with mass spectrometry. journals.plos.org/ploscompbiol...
06.07.2025 08:02 β π 4 π 0 π¬ 2 π 0Our latest work is out: we designed dual GLP1R/GCGR agonistsβcyclic peptides that activate both metabolic receptors, entirely from sequence alone.
This has never been done before. www.biorxiv.org/content/10.1...
You can also design in Colab now: colab.research.google.com/github/patri...
27.05.2025 12:40 β π 8 π 2 π¬ 0 π 0The WT binder is 1.8 uM which means that we create as good binders but with new modes of binding for a target where these NCAA interactions are completely unknown π
25.05.2025 20:04 β π 1 π 0 π¬ 0 π 0Thanks! We will release a lot of new tech this year - stay tuned! We are only in the beginning of protein design I think
25.05.2025 20:02 β π 2 π 0 π¬ 0 π 0There is also an audio summary generated by Science Cast here: sciencecast.org/casts/4kj8lr...
25.05.2025 14:11 β π 0 π 0 π¬ 0 π 0Just like we have used EvoBind to e.g. create functional HIV inhibitors in a single shot (biorxiv.org/content/10.1...) we can now do this with an expanded vocabulary to have more chemical possibilities and avoid e.g. immune recognition and degradation
25.05.2025 14:11 β π 0 π 0 π¬ 1 π 0RareFold supports 49 different AAs.
The 20 regular, and 29 rare ones: MSE, TPO, MLY, CME, PTR, SEP,SAH, CSO, PCA, KCX, CAS, CSD, MLZ, OCS, ALY, CSS, CSX, HIC, HYP, YCM, YOF, M3L, PFF, CGU,FTR, LLP, CAF, CMH, MHO.
You can simply specify which you want to use and design!
Happy to release our breakthrough AI-model: RareFold, which predicts and designs proteins with noncanonical AAs. With EvoBindRare, we designed linear & cyclic peptide binders with high affinity & novel binding modes, wet lab validated.
π biorxiv.org/content/10.1...
π» github.com/patrickbryan...